[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-headache":296},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,60,87,110,143,167,189,216,239,266],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100551403",false,"NCT06459635","Migraine Attack Pain Phase Prediction Study","Prediction Study of the Pain Phase of Migraine Attacks in Patients With Episodic Migraine","PREDI-CRISIS","Inclusion Criteria:\n\n* Age between 15 years and 69 years.\n* Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.\n* History of migraine of at least 1 year of evolution.\n* Normal neurological examination.\n* Have given your informed consent.\n* Be able to describe your clinical situation and the characteristics of your headache.\n* Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).\n* User-level management capacity of \"smartphone\" type electronic devices.\n* Be able to complete two months of study follow-up.\n\nExclusion Criteria:\n\n* Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.\n* Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.\n* Neurological focus in the examination.\n* Pregnancy or breastfeeding period.\n* Patients with known heart disease or bronchopathy, Sjögren\\'s syndrome, diabetes mellitus, or hypo\u002Fhyperthyroidism.\n* Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.\n* Anatomical problem that makes the use of the device impossible.\n* Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},70,"ESTIMATED","2 Months","OBSERVATIONAL","The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.",[27,28,29,30,31],"Migraine","Migraine Headache","Migraine Disorders","Migraine Without Aura","Migraine With Aura",[27,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Headache","Predict","Prediction","headache prediction","predict headache","migraine prediction","predict migraine","migraine attacks","migraine attack","headache attack","migraine attack prediction","predict migraine attack","prediction algorithm","algorithm","RECRUITING","2026-06-30",{"date":50,"type":51},"2026-07-02","ACTUAL",{"date":53,"type":51},"2023-10-09",{"date":55,"type":22},"2026-07",{"name":57,"class":58},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","OTHER",1,{"id":61,"slug":4,"hasResults":10,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":59},"100619758","NCT07348783","Yogabased Movements for Primary Headaches (Migraine and\u002For Cluster Headache) - YOURHEAD","Yogabased Movements Weekly (Online Live or Face to Face) for Primary Headaches","Inclusion Criteria:\n\n* Diagnosed chronic migraine and\u002For cluster (Hortons) headache\n* Men and women 18-65 years\n* Diagnosed with chronic\u002Fhigh frequency migraine (≥15 headache days\u002Fmonth with at least ≥8 with migraine)\n* Diagnosed with chronic cluster head ache (i.e shorter remission than 3 months per year), diagnosed according to ICHD-III criteria.\n* Ability to perform yoga based moments and to give consent.\n* Internet connection with computer\u002Fipad\u002Fmobile to perform digitally\u002Ftele-health instructions\n* Willing to use wristwatch for actigraphy\n* Willing to leave blood samples in laboratory\n\nExclusion Criteria:\n\n* Recent or planned operations during the last 6 weeks\n* Drug dependence, alcohol dependence, mental disorders as psychosis, bipolar disorder, anxiety as PTSD etc)\n* Parallel enrollment in other clinical trails\n* Unmedicated high blood pressure, heart disease as heart failure\n* Non Swedish speaking\n* Not able to perform low intensity exercise at home or FTF (face to face) - both online or live.\n* Participants unsure to participate due to drug addiction or other causes\n* Disorientation and not able to inform regarding other serious conditions",{"count":67,"type":22},80,"INTERVENTIONAL",[70],"NA","Brief Summary:\n\nMigraine and\u002For Cluster Headache: Study Overview\n\n\\*\\*Background:\\*\\* Migraine and cluster headache are two primary headache disorders that significantly impact quality of life and functionality in those affected. According to the WHO's recurring burden of disease reports, migraine is among the neurological conditions responsible for the highest number of years lost due to illness. The headaches associated with migraine and cluster headache range from moderate to severe and cause great suffering. Available treatments do not work for everyone and are often associated with adverse side effects. Physical activity has been shown in several studies to have a positive effect on headache. Given the high prevalence of mental health issues, stress, and sleep problems within this patient group, relaxation and low-intensity exercise such as yoga-based movements (YB) could potentially help individuals improve sleep and well-being, while also providing some preventive effect on headaches.\n\n\\*\\*Hypothesis:\\*\\*\n\nIndividuals with severe migraine or cluster headache have a strong need for new treatment options. Alternative therapies such as yoga-based exercises, when combined with standard medical treatment as per clinical guidelines, may positively impact:\n\nHeadache symptoms, Sleep quality and Overall life quality\n\n* Purpose and Goals:\\*\\* This randomized controlled study aims to evaluate the effect of a web-based yoga (YB) or live face to face (FTF) intervention in individuals suffering of primary headaches-mainly chronic migraine and\u002For cluster headache. The study will assess the effect of YB on health-related changes in headache frequency, intensity, and duration associated with primary headache conditions, with a focus headache frequency. A secondary objective is to analyze quality of life, sleep quality, mental health as depression and anxiety. The RCT will also measure objective sleep and biomarkers. We are now summarizing the effects after a pilot study.\n* Relevance for the Patient Group:\\*\\* The core objective of the project is to determine whether yoga-based exercises can serve as a complementary treatment to enhance quality of life and health in patients with severe primary headache. To ensure equal healthcare access, this intervention will be delivered in digital format and\u002For FTF to optimize availability and expand care for individuals with primary headache disorders. These efforts aim to improve life quality and well-being in a vulnerable patient population. Headache conditions often affect individuals in their most productive years, and many live with symptoms for decades. Both work and private life are frequently disrupted, resulting in sick leave and social isolation. Close relatives are also affected, as those suffering from headaches require more recovery time to cope with daily life. With this proposed project, we aim to use physical yoga, rooted in holistic traditional medicine, to help individuals with severe primary headache achieve better physical and mental health-particularly improved sleep quality, which in turn enhances overall life quality.",[73,28,74,75,76,77],"Cluster Headache - Episodic and Chronic","Migraine Headache, With or Without Aura","Migraine in Adults","Cluster Headaches and Other Trigeminal Autonomic Cephalgias","Migraine Disorder","2026-06-23",{"date":80,"type":51},"2026-06-26",{"date":82,"type":51},"2026-05-01",{"date":84,"type":22},"2027-12-30",{"name":86,"class":58},"Karolinska Institutet",{"id":88,"slug":4,"hasResults":10,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":68,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":59},"100643927","NCT07667621","A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department","A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department","Inclusion Criteria:\n\n* • At least 18 years of age\n\n  * Capacity to provide informed consent (without a Representative)\n  * Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is \\>72 hours. Must have been headache free for \\>48 hours prior to current attack.\n  * Willing to participate in post-discharge telephone assessments\n  * English and\u002For Spanish speaking patients\n\nExclusion Criteria:\n\n* • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant.\n\n  * Use of analgesics or abortive headache medications within 60 minutes of study medication administration\n  * Use of the following drug\u002Ffood categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors\u002Finducers, 5) NTCP transporter potent inhibitors\u002Finducers\n  * History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable\n  * History of any stroke within 3 months, or any lifetime stroke and age ≥65 years\n  * History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate\n  * History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure)\n  * History of severe hepatic impairment, as assessed by the investigator or qualified delegate\n  * History of kidney disease stage 4 (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n  * History of hypersensitivity reaction to rimegepant, zavegepant, or to any included inactive ingredients\n  * Lifetime use of CGRP-targeting acute or preventive migraine medications\n  * In custody of law enforcement\n  * Current pregnancy or lactation\n\n    * All individuals of childbearing potential must have a negative pregnancy test at screening (urine or serum).\n    * A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).",{"count":94,"type":22},100,[96],"PHASE1","Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.",[27,99,75,28,100,30,31],"Migraine Disease","Acute Migraine","NOT_YET_RECRUITING","2026-06-20",{"date":104,"type":51},"2026-06-25",{"date":55,"type":22},{"date":107,"type":22},"2027-08",{"name":109,"class":58},"University of South Florida",{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":116,"targetDuration":4,"studyType":68,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":59},"100643788","NCT07634146","Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","A Randomized, Sham Supplement- and Care-as-Usual-Controlled Study to Evaluate Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","Inclusion Criteria:\n\n* Self-reported history of migraine, based on the International Headache Society (IHS) International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria for migraine.\n* Being able to take oral supplements.\n* Agreeing to maintain their regular lifestyle.\n* Access to internet and telephone.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Presence of any active medical condition or diagnosis other than episodic migraine, including liver or kidney disease or condition.\n* Use of overlapping supplements or interacting medications.\n* Known allergies to study ingredients.\n* Daily use of alcohol, tobacco, or recreational drugs.\n* Participation in any other clinical or interventional study within 30 days prior to baseline or concurrently.",{"count":117,"type":22},920,[70],"The purpose of this study is to evaluate the impact of the Migraceutics® phase-specific dietary supplement regimen on quality of life, work productivity, and biomarkers in adult migraineurs.",[27,99,77,28,121,75,122,123],"Migraine Disability","Menstrual Migraine","Menstrual Migraine (MM) Headaches",[125,126,127,128,129,130,131,132,133],"quality of life","productivity","disability","CGRP","headache","migraine","nutraceuticals","dietary supplement","migraceuticals","2026-06-03",{"date":136,"type":51},"2026-06-08",{"date":138,"type":22},"2026-07-08",{"date":140,"type":22},"2028-06-30",{"name":142,"class":58},"Miracle Wellness LLC",{"id":144,"slug":4,"hasResults":10,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":68,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":59},"100629544","NCT07476053","Light Exposure, Migraine Outcomes, and Sleep Quality","Daily Light Exposure Patterns and Their Associations With Migraine Outcomes and Sleep Quality","Inclusion Criteria:\n\n* Meet the International Classification of Headache Disorders, 3rd edition (2018) criteria for migraine, with or without aura or photosensitivity\n* Report experiencing more than 4 headache days per month and at least three migraine attacks per month\n* No other major health issues based on self-reported data\n* Able to read and communicate in English\n* Work in a private office space for at least six hours per day, four days per week\n\nExclusion Criteria:\n\n* Light therapy\n* Use light-altering devices (e.g., blue-blocking contact lenses or glasses)\n* Traveling out of town during the participation",{"count":150,"type":22},20,[70],"The purpose of this study is to examine the relationship between daily light exposure patterns, sleep quality, and migraine characteristics in adults with migraine, with and without photophobia, across an 8-week study period.",[28,154,155],"Sleep","Photophobia",[27,154,157,155],"Lighting","2026-04-23",{"date":160,"type":51},"2026-04-28",{"date":162,"type":51},"2026-03-24",{"date":164,"type":22},"2027-03",{"name":166,"class":58},"Arizona State University",{"id":168,"slug":4,"hasResults":10,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":173,"targetDuration":4,"studyType":68,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100531751","NCT06203873","A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine","BioMetal","Inclusion Criteria:\n\n1. Age 18-65\n2. Diagnosed migraine by ICHD-3\n3. History of migraine longer than 1 year, and symptoms severely disturbing daily life.\n4. TCD\u002FTTE\u002FTEE diagnosed patent foramen ovale with right to left shunt\n5. Willing to participant and agree to follow-ups\n6. Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.\n\nExclusion Criteria:\n\n1. Migraine caused by other reason\n2. Had TIA\u002Fstroke history\n3. With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.\n4. With contraindication to PFO occlusion",{"count":174,"type":22},400,[70],"Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults. Mechanisms linking PFO to migraine include cortical spreading depression, vascular active substance theory, impaired cerebral autoregulation, and genetic susceptibility. Understanding these mechanisms holds promise for overcoming challenges in the prevention and treatment of migraines in PFO patients. At least 11 observational studies, comprising 1,632 subjects, described the efficacy of PFO closure in cryptogenic stroke. Of these, 34% had migraines, and percutaneous PFO closure reportedly reduced migraine days by 81% (with a reduction of over 50% in monthly migraine days). Prospective randomized controlled trials (PRIMA and PREMIUM trials) assessing the Amplatzer® PFO Occluder showed significant benefits in most secondary endpoints, with a pooled analysis indicating its safety and effectiveness compared to medical therapy.While traditional metal PFO closure studies suggest symptom relief, reports also mention potential new-onset or worsened migraines post-closure. Proposed mechanisms include platelet activation, microthrombus formation, nickel allergy, and septal deformation or stretching inducing the release of migraine-related vascular active substances. However, these theories are closely tied to the presence of permanent metal implants.\n\nAddressing these concerns, the MemoSorb® biodegradable PFO Occluder system, approved by the National Medical Products Administration (NMPA) in September 2023, offers an innovative solution. Developed collaboratively by the National Biomedical Materials Engineering Technology Research Center, Professor Wang Yunbing\\'s team, Professor Pan Xiangbin\\'s team from Fuwai Hospital, Chinese Academy of Medical Sciences, and HeartTech Medical, this groundbreaking technology represents a shift from metal to degradable materials. The occluder serves as a temporary bridge post-implantation, gradually degrading with endothelialization, facilitating comprehensive self-repair. This intervention concept theoretically avoids the lifelong complications associated with traditional metal occluders, effectively reducing postoperative symptoms like migraines and dizziness.\n\nTo assess and compare the treatment outcomes, especially in relieving migraines, a prospective, single-blind, randomized controlled study has been designed for patients with patent foramen ovale and migraine, comparing the novel biodegradable occluder with the metal occluder.",[178,27,28,74],"PFO - Patent Foramen Ovale","2025-11-27",{"date":181,"type":51},"2025-12-04",{"date":183,"type":51},"2024-03-01",{"date":185,"type":22},"2026-03-01",{"name":187,"class":58},"Chinese Academy of Medical Sciences, Fuwai Hospital",2,{"id":190,"slug":4,"hasResults":10,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":68,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":59},"100511747","NCT05943457","Vitamin K2 Supplementation in Adult Episodic Migraine","Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine","ViKEM","Inclusion Criteria:\n\n* Adults aged 18 years or above\n* History of episodic migraine with or without aura since \\> 12 months according to the ICHD-3 criteria.\n* Migraine frequency from 4-14 days per month over the 3 months prior to screening.\n* Migraine frequency from 4-14 days per month during the baseline period of assessment.\n* Successful completion of the migraine diary during the baseline evaluation period.\n\nExclusion Criteria:\n\n* Migraine patients with superimposed tension type or other forms of primary headaches\n* Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan)\n* Patients who have been on any of the previously listed medications within 3 months of screening\n* Patient who takes the following medications:\n\n  * Ergotamine or Triptans \\> 10 days per month\n  * NSAIDs or paracetamol \\> 15 days per month\n  * Opioids more than 4 days per month\n  * Patients on anticoagulants\n* Other active chronic pain syndromes (i.e. fibromyalgia, painful peripheral neuropathy, post-herpetic neuralgia…)\n* History of hypersensitivity to the vitamin K2\n* History of soy protein, cheese, eggs and meat allergy\n* History of thrombotic events\n* Diagnosed coagulopathy or any condition related to coagulation\n* Cardiovascular event in the past month\n* Current or planned pregnancy\n* Lactation\n* Inability to tolerate oral medications\n* Known intestinal malabsorption or hypomotility syndromes\n* Atrial fibrillation\n* Active malignancy\n* Any acute illness in the past month",{"count":197,"type":22},160,[70],"Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.",[28,201,202],"Arterial Stiffness","Vitamin K Deficiency",[27,204,205,206],"Arterial stiffness","Vitamin K deficiency","Migraine attack","2025-11-14",{"date":209,"type":51},"2025-11-18",{"date":211,"type":51},"2024-03-06",{"date":213,"type":22},"2026-12",{"name":215,"class":58},"Sola Aoun Bahous, M.D. Ph.D.",{"id":217,"slug":4,"hasResults":10,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":68,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":59},"100594672","NCT07022496","Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals","Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.\n\nExclusion Criteria:\n\nPatients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded","60 Years",{"count":224,"type":22},120,[226],"PHASE4","Caffeine extracted from green tea to abort acute attack of Migraine",[27,99,28,74,229],"Migraine, Acute","2025-06-07",{"date":232,"type":51},"2025-06-15",{"date":234,"type":51},"2023-04-26",{"date":236,"type":22},"2025-08",{"name":238,"class":58},"Ain Shams University",{"id":240,"slug":4,"hasResults":10,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":68,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":59},"100594128","NCT07015411","Neuro-Complex & Multi Supplements for Migraine Prevention","Effectiveness of an Orally Administered and Combined Neuro-Complex & Multi Supplements in the Prevention of Migraine in Adult","NeuroCare","Inclusion Criteria:\n\n* Male or female between 18 and 75 years;\n* Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)\n\n  * At least 5 attacks fulfilling the criteria below\n  * Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)\n  * Headache has at least two of the following characteristics\n\n    * unilateral location\n    * pulsating quality\n    * moderate or severe pain intensity\n    * aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)\n  * During headache at least one of the following:\n\n    * nausea and\u002For vomiting\n    * photophobia and phonophobia\n  * Not attributed to another disorder\n* Migraine frequency of at least 6 headache days per month during the last 3 months;\n* Stable body mass index (BMI) between 18.5-35.0;\n* Stable medication use with no significant changes in prophylactic or acute migraine treatments in the past 3 months, and willingness to maintain or reduce (if not needed) this throughout the study period;\n* Willingness and ability to complete an ediary (mobile app or web based) and to follow the instruction of the study;\n* Having signed an informed consent.\n\nExclusion Criteria:\n\n* Other primary head pain disorders such as but not restricted to tension-type headache, cluster headache, fibromyalgia;\n* Secondary head pain due to trauma, injury, infections;\n* Medication overuse for headache defined as acute headache medication \\>10-15 days per month depending on the half-life of the medication (left to PI discretion);\n* Severe medical conditions affecting absorption and metabolism of the product, including but not restricted to chronic use of laxatives;\n* Bariatric surgery;\n* Severe psychiatric conditions that could interfere with diary compliance or assessment of the product (e.g., severe depression or cognitive impairments) left to investigator discretion;\n* Use of other dietary supplements that could potentially affect migraines, unless willing to discontinue them before the study begins (wash out period of 3 months);\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;\n* Women of childbearing potential without medically effective form of contraception unless they can confirm they've had bilateral tubal ligation or that their male partner has had a vasectomy;\n* Specific allergies or intolerance to components of the product;\n* Recent migraine interventions: Such as Botox injections (except if considered as a stable treatment, i.e. not the first injection), nerve blocks, or other invasive treatments in the last 6 months;\n* Concurrent participation in another clinical study or having participated in the last 3 months:\n* Swallowing disorders;\n* Chronic drug and alcohol abuse;\n* Anticoagulants (coumarin compound);\n* Hepatic or biliar truct disorders;\n* Active malignancy and immunosuppression therapy;\n* Hypothyroidism;\n* Close collaborators of investigational team, of sponsor or of study coordinator;\n* Under guardianship or judiciable protection.","75 Years",{"count":224,"type":22},[70],"The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \\& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura).\n\nThe main endpoint of this clinical trial is :\n\nThe mean changes in migraine days per month (MDM) after 8 weeks of supplementation.\n\nParticipants will:\n\nOrally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).",[28,27,75],[27,252,253,254,129,255],"Neuro-Complex","Multi","Supplement","nutrients","2025-06-03",{"date":258,"type":51},"2025-06-11",{"date":260,"type":51},"2025-05-15",{"date":262,"type":22},"2025-12-16",{"name":264,"class":265},"Benfida, a department of Handi-Move","INDUSTRY",{"id":267,"slug":4,"hasResults":10,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":16,"sex":17,"minAge":273,"maxAge":246,"enrollmentInfo":274,"targetDuration":276,"studyType":24,"phases":4,"briefSummary":277,"conditions":278,"keywords":285,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":59},"100567944","NCT06674772","Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification","Fenotipado Molecular De Pacientes Con Migraña Según Edad Y Sexo a Través De La Cuantificación De CGRP En Saliva Para Realizar Medicina De Precisión: Estudio FAST","FAST","Inclusion Criteria:\n\n* Migraine patients according to ICHD-3 criteria\n* Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.\n\nExclusion Criteria:\n\n* Presence of any major medical or neurological illness.\n* Presence of any salivary gland malfunction.\n* Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.\n* Active migraine preventive treatment.\n* Pregnant or breastfeeding female.","6 Years",{"count":275,"type":22},440,"1 Day","Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.",[279,27,28,280,30,281,282,283,284],"Headache (Migraine)","Migraine with Aura","Episodic Migraine","Chronic Migraine Headache","Chronic Migraine, Headache","Episodic Migraine Headache",[27,128,286],"saliva","2024-11-11",{"date":289,"type":51},"2024-11-13",{"date":291,"type":51},"2022-11-29",{"date":293,"type":22},"2025-05",{"name":295,"class":58},"Hospital Universitari Vall d'Hebron Research Institute",""]